| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8178693 | ASTRAZENECA | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar, 2023
(1 year, 1 month ago) | |
| US7425637 | ASTRAZENECA | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar, 2024
(a month ago) | |
| US9562017 | ASTRAZENECA | Hydrogen sulfate salt |
Dec, 2026
(2 years from now) | |
| US9156795 | ASTRAZENECA | Hydrogen sulfate salt |
Dec, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11813246 | ASTRAZENECA | Pharmaceutical composition |
Mar, 2029
(4 years from now) | |
Koselugo is owned by Astrazeneca.
Koselugo contains Selumetinib Sulfate.
Koselugo has a total of 5 drug patents out of which 2 drug patents have expired.
Expired drug patents of Koselugo are:
- US8178693
- US7425637
Koselugo was authorised for market use on 10 April, 2020.
Koselugo is available in capsule;oral dosage forms.
Koselugo can be used as treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (nf1) who have symptomatic, inoperable plexiform neurofibromas (pn).
Drug patent challenges can be filed against Koselugo from 10 April, 2024.
The generics of Koselugo are possible to be released after 26 March, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 10, 2025 |
| Orphan Drug Exclusivity(ODE-288) | Apr 10, 2027 |
Drugs and Companies using SELUMETINIB SULFATE ingredient
NCE-1 date: 10 April, 2024
Market Authorisation Date: 10 April, 2020
Treatment: Treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (nf1) who have symptomatic, inoperable plexiform neurofibromas (pn)
Dosage: CAPSULE;ORAL
KOSELUGO family patents
